Researchers explore the cellular and molecular adaptations associated with human secondary lymphoid tissue in adults during ...

Mozart Therapeutics, the leading developer of CD8 Treg network modulators in autoimmune disease, announces the presentation ...

The Phase 1b/2a study will assess the safety of CNP-103 in adults (aged 18-35) and pediatrics (aged 12-17) who have Stage III or newly diagnosed (within the last 6 months) T1D as well as C-peptide ...